AEPWM
RDHL

Atlantic Edge Private Wealth Management’s Redhill Biopharma RDHL Stock Holding History

Atlantic Edge Private Wealth Management’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1
Closed -$37 – 504
2023
Q4 		$37 Buy
+1
New +$20 ﹤0.01% 468

Other funds holding RDHL

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
MOS
MGO One Seven Beachwood, Ohio $4.98B AUM 22.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Atlantic Edge Private Wealth Management's RDHL Position: Q1 2024 in Review

Atlantic Edge Private Wealth Management sold out of Redhill Biopharma (RDHL) in Q1 2024, closing a stake of 1 share — an estimated $37 sold.

Atlantic Edge Private Wealth Management first reported a position in RDHL in Q4 2023 and held it in 1 quarter. The position peaked at $37 in Q4 2023. 15 funds tracked by Wall St. Rank hold RDHL as of Q1 2024.

  • Atlantic Edge Private Wealth Management reported no remaining Redhill Biopharma position as of Q1 2024 after selling out during the quarter.
  • Atlantic Edge Private Wealth Management sold 1 Redhill Biopharma share in Q1 2024, an estimated $37.
  • Atlantic Edge Private Wealth Management first reported a position in Redhill Biopharma in Q4 2023 and held it in 1 quarter.
  • Atlantic Edge Private Wealth Management's Redhill Biopharma position peaked at $37 in Q4 2023.
  • 15 funds tracked by Wall St. Rank held Redhill Biopharma as of Q1 2024.

Based on Atlantic Edge Private Wealth Management's 13F filing for Q1 2024, filed 8 May 2024.